StreetAlpha.app
Home › Stocks › CMPS

COMPASS Pathways plc (CMPS)

Healthcare
Members
LATEST PRICE

COMPASS Pathways is a UK biotechnology company developing COMP360, a psilocybin-based treatment for serious mental health conditions. CMPS reports earnings on Tue, Nov 3, 2026.

Prices, price targets and earnings estimates for CMPS are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plans
AI Auto Pilots
Is CMPS in one of our four AI portfolios? Sign in free to see
See how it works→ Details ↓

Earnings

Earnings calendar →
Next report
Nov 3
2026 · Time not announced
Consensus EPS forecast
Members
EPS and revenue estimates
Year-ago EPS
Members
Same quarter last year
Options-implied move
Members
Move priced in by options
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated CMPS in the past 90 days, not enough for a consensus
Average 12-month target
Price targets for CMPSThe average, highest and lowest analyst targets and the target chart are shown to AI Starter and AI Pro members.See plans
Latest rating changes
HC Wainwright & Co.Maintained
Aug 7Buy
B. Riley SecuritiesTarget raised
Aug 6Buy
Wells FargoInitiated
Jul 27Hold
Evercore ISI GroupUpgrade
Jul 8Buy
StifelMaintained
Jul 8Buy
DateFirmActionRatingPrice target
Aug 7HC Wainwright & Co.MaintainedBuy
Aug 6B. Riley SecuritiesTarget raisedBuy
Jul 27Wells FargoInitiatedHold
Jul 8Evercore ISI GroupUpgradeBuy
Jul 8StifelMaintainedBuy
Loading…

Whale Options Flow

90D

No whale options trades in CMPS in the last 90 days.

Loading…

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CMPS is in one of them and how their past CMPS trades turned out.

See how it works→ View all auto pilots→
CMPS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CMPS in an article yet. Here's the latest on the wider market.

macronewsFriday, October 30, 2026
Binance and Polymarket Hacks Test Crypto's Plumbing, Not Yet Macro
Binance paused withdrawals after a suspected theft of roughly $6 billion, while Polymarket halted trading for an hour after a vendor breach.
Jean Westart · 3 min read
macronewsMonday, October 26, 2026
S&P 500 Sits 2.5% Below Its Record Ahead of the Fed and Big Tech
The S&P 500 slipped 0.47% to 7,623.68, 2.5% below its record, as the Fed meets October 28 and Alphabet, Microsoft and Amazon report.
Marie Crown · 3 min read
macronewsMonday, October 26, 2026
Hightower's Stephanie Link Tells Investors to Add on Volatility
Hightower's Stephanie Link told CNBC's Squawk Box that investors should use market volatility to add to portfolios as earnings season unfolds.
Adam Landser · 2 min read

About COMPASS Pathways

COMPASS Pathways is a biotechnology company based in the United Kingdom. It is developing COMP360, a treatment built around psilocybin for serious mental health conditions, with its current focus on depression that has not responded to standard medicines. The company is also running a clinical trial for PTSD. If approved, it plans to offer the treatment to patients through healthcare providers in the U.S.

Headquarters
Chesire, United Kingdom
Founded
2016
Summary based on the company’s 2026 annual report (10-K) ↗